18 Aug 2017 07:00
Â
Â
Â
Â
NMC Health plc to Report Interim 2017 Results on 23 August 2017
Â
Â
London, 18 August 2017:Â NMC Health plc (the "Company") will report its interim 2017 financial results (for the six months to 30 June 2017) on Wednesday, 23 August 2017.
Â
The results are expected to be published on the Regulatory News Service at 7am UK time on that day, and shortly thereafter on the Company's website at http://www.nmchealth.com/investor-relations/.
Â
Contacts
Â
NMC | Â |
Prasanth Manghat, Deputy Chief Executive Officer | +971 (0)50 522 5648 |
Suresh Krishnamoorthy, Chief Financial Officer Asjad Yahya, Investor Relations  | +971 (0)50 591 5365 +971 (0)56 219 0975 |
Media | |
FTI Consulting, London | Â |
Brett Pollard / Mo Noonan | +44 (0)20 3727 1100 |
 | |
FTI Consulting, Gulf | Â |
Shane Dolan | +971 (0)4 437 2100 |
Â
About NMC Health
The NMC group (the "Group") is the leading private sector healthcare operator in the United Arab Emirates, with a nation-wide network of hospitals and operations in the country since 1975. The Group currently operates or manages eight hospitals, two day-care patient centres, nine medical centres and fifteen pharmacies. In addition, the Group owns and operates Clinica Eugin in Barcelona, Spain - one of the leading fertility treatment centres globally. NMC also owns a 51 per cent. shareholding in Fakih IVF Group, the Middle East market leader for in-vitro fertilisation ("IVF") services. Moreover, NMC also owns and operates Americare Group, the leading home care provider in the UAE as well as ProVita, the pioneering provider of long-term medical care, also in the UAE. The enlarged company received almost 4.3 million patients in 2016. The Group is also a leading UAE supplier of products and consumables across several key market segments, with the major contribution coming from healthcare related products. The Group reported revenues of US$1,220.8 million for the year ended 31 December 2016.
Â
In April 2012 NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 250 Index.